Clinical trials: Individual Difference, open to volunteers
- Condition Individual Difference
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity
This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity…
- Trial name
- NCT07731139
- Testing
- PF-08642534
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight.
- Trial name
- RENEW 4 (NCT07745504)
- Testing
- Cagrilintide
- Where
- 36 sites in United States, Greece and 4 more
- Volunteers
- 285 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
The main objective of this trial is to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.
- Trial name
- NCT07845630
- Testing
- Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pertussis (Whooping Cough), Diphtheria
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07894055
- Testing
- Tdap vaccine
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
- Trial name
- NCT04886804
- Testing
- zongertinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 554 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this…
- Trial name
- NCT07553429
- Testing
- Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related…
- Trial name
- NCT07754474
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer Extensive Stage
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body.
- Trial name
- NCT07227597
- Testing
- Gocatamig, I-DXd, Atezolizumab
- Where
- 57 sites in United States, Argentina and 11 more
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3814916 in healthy male and female trial participants.
- Trial name
- NCT07486115
- Testing
- BI 3814916
- Where
- Belgium
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
Diabetes Mellitus, Type 2
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes.
- Trial name
- NCT07668388
- Testing
- UBT251, Semaglutide
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways
The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.
- Trial name
- NCT07837648
- Testing
- BI3034701 formulation II, BI3034701 formulation C1
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumours
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This study is open to adults with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer…
- Trial name
- NCT07744152
- Testing
- BI 3822971
- Where
- 11 sites in Belgium, China and 3 more
- Volunteers
- 137 people
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment, Healthy, Hepatic Insufficiency
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.
- Conditions
- Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
- Trial name
- NCT07677358
- Testing
- Atirmociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Solid Tumors
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists.
- Trial name
- NCT05471856
- Testing
- BI 1703880, Ezabenlimab
- Where
- 21 sites in United States, Japan and 4 more
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 administrations of multiple rising doses.
- Trial name
- NCT07908004
- Testing
- BI 3821001
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Conditions
- Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05882058
- Testing
- BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim